A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

Jonas Mandel (1) , Viviane Bertrand (1) , Philippe Lehert (2, 3) , Shahram Attarian (4) , Laurent Magy (5) , Joëlle Micallef (6) , Ilya Chumakov (1) , Catherine Scart-Grès (1) , Mickael Guedj (1) , Daniel Cohen (1)

1 Pharnext SAS
2 Faculty of Medicine
3 Faculty of Economics
4 GMGF - Génétique Médicale et Génomique Fonctionnelle
5 CHU Limoges
6 INT - Institut de Neurosciences de la Timone

CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with AA were stable after one year but not significantly different from Placebo. Patients undergoing PXT3003 treatment showed an improvement in CMTNS and ONLS, statistically significant versus Placebo and potentially precursory of a meaningful change in the disease course.

Mots clés: Charcot-Marie-Tooth; CMT1A; CMTNS; ONLS; Meta-analysis; Ascorbic acid; Clinical trials; Randomized; Double blind; MARIE-TOOTH-DISEASE; ASCORBIC-ACID TREATMENT; NEUROPATHY SCORE; PERIPHERAL NEUROPATHY; 2ND VERSION; 1A; RELIABILITY; COMBINATION; EXPRESSION; PXT3003

Domaines: Sciences du Vivant [q-bio]; Neurosciences [q-bio.NC]; Médecine humaine et pathologie

Jonas Mandel, Viviane Bertrand, Philippe Lehert, Shahram Attarian, Laurent Magy, et al.. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet Journal of Rare Diseases, 2015. ⟨hal-01203428⟩